Heme oxygenase is the key enzyme in the mammalian heme degradation pathway. It catalyzes the conversion of heme to biliverdin IXα, CO and free iron in a reaction that utilizes three molecules of molecular oxygen and seven electrons provided by NADPH-P450 reductase ( Fig.   1 ) (1, 2) . The biliverdin is subsequently reduced to bilirubin by biliverdin reductase and is then excreted as the glucuronic acid conjugate (3) . Heme oxygenase and its products are now known to contribute to diverse physiological protective mechanisms. First, biliverdin and bilirubin are potent antioxidants (4) . Second, heme oxygenase removes non-specifically bound heme, which is a source of noxious free radicals and other oxidizing species. Third, CO has anti-inflammatory effects mediated via the mitogen-activated protein kinase pathway (5, 6) . Finally, heme oxygenase is essential for cellular iron homeostasis because heme catabolism is by far the principal source of iron in the body (7) . Recent studies have reported the potential importance of heme oxygenase and its products in the treatment of various disorders, including cardiovascular diseases, cancer, and allograft tissue rejection (8) (9) (10) (11) (12) . However, as found in Criggler-Najar patients and in neonatal jaundice (13) , high concentrations of unconjugated bilirubin are neurotoxic.
Three heme oxygenase isoforms, HO-1, HO-2 and HO-3, have been reported in humans and other mammals. HO-1, a stress responsive protein that is induced by a variety of stimuli (13, 14) , is present in highest concentration in spleen and liver. A truncated human HO-1 construct lacking the 23 C-terminal amino acids (amino acids 1-265, denoted hHO-1) has been heterologously expressed and is both water soluble and fully active (15) . Successful expression of hHO-1 in Escherichia coli has greatly facilitated characterization of this enzyme. HO-2, a constitutive isoform that is enriched in the brain and testes, may be involved in CO signaling pathways (16, 17) . HO-3 is the least characterized isoform and its physiological role, if any, remains unclear (18) .
The aerobic oxidation of heme in solution in the presence of ascorbic acid, a process termed coupled oxidation, can occur at any of the four meso positions and thus yields a mixture of the four possible biliverdin isomers: i.e., biliverdin IXα, β, γ, and δ. In contrast, the mammalian heme oxygenases cleave heme exclusively at the α-meso position (Fig. 1) . Heme oxygenase catalysis is initiated by hydroxylation of the α-meso-carbon to give α-mesohydroxyheme (2) . In this oxidation, one electron from NADPH-P450 reductase is used to reduce the iron from the ferric to the ferrous state. A molecule of oxygen then binds to give a ferrous dioxygen complex that is reduced by a second electron from NADPH-P450 reductase to the ferric hydroperoxo complex (i.e., Fe(III)-OOH). Electrophilic attack of this peroxo complex on the α-meso-carbon of the heme yields Fe(III) α-meso-hydroxyheme. The next step in the sequence is the oxygen-dependent conversion of Fe(III)α-meso-hydroxyheme to Fe(III) verdoheme, which is then oxidized to Fe(III)-biliverdin in a reaction that consumes a further two electrons and a molecule of oxygen (2) . In the concluding steps of the sequence, the ferric iron is reduced to the ferrous state and is then released, and finally the biliverdin is released in a process that is facilitated by biliverdin reductase (19) . Crystal structures are now available of human hHO-1 in the substrate-free (20) , substrate-bound (21, 22) , verdoheme-bound (23) , and biliverdin bound (24) states. A structure is not available for the α-meso-hydroxyheme-or iron biliverdin-bound states of human hHO-1, but a structure of the latter form is available for a similarly truncated rat HO-1 (25) .
The crystal structures of the heme-hHO-1 complexes suggest that the regiospecificity of the reaction is controlled, at least in part, by steric interactions between the distal helix and the heme that favor attack of the Fe(III)-OOH on the α-meso-carbon (21, 22) . However, placing a substituent on the α-meso-carbon can alter the reaction regiospecificity. Thus, α-mesomethylheme is still exclusively oxidized at the methyl-substituted position (26) , but α-mesoformylheme is only oxidized at the non-formyl-substituted meso-carbons (27) . The finding that the methyl and formyl groups channel the reaction regiospecificity in opposite directions suggests that the regiochemistry is to some extent under electronic as well as steric control.
In bacteria, the heme oxygenases from Corynebacterium diphtheriae (cd-HO) and Neisseriae meningitidis (nm-HO) oxidize heme only at the α-meso position (28, 29) . However, the enzyme from Pseudomonas aeruginosa (pa-HO), which has 37% amino acid sequence identity with nm-HO, oxidizes heme to biliverdin IXδ (70%) and IXβ (30%) (30, 31) . The novel β-regioselectivity of heme oxygenation by pa-HO has been reported to be due to an unusual seating of the heme that allows rotation about an axis through the iron perpendicular to the porphyrin plane (31, 32) . In pa-HO, the heme is rotated by ~100°, which places the δ-meso carbon in the same position as the α-meso heme carbon in other heme oxygenases. Interactions between the heme propionate groups and the protein appear to play an important role in properly orienting the heme. Disruption of these interactions by mutagenesis can alter the regiochemistry of the oxidation promoted by pa-HO (33) .
In rat and human heme oxygenase, Arg183 interacts with the heme propionate through a hydrogen bond (21, 22) . It has been reported that the mutations R183E and R183D in rat heme oxygenase alter the enzyme regiospecificity, resulting in formation not only of biliverdin IXα but also of IXδ (35%) in the ascorbate-dependent reaction (34) . Here we report studies of the R183E mutant of human hHO-1 that shed light on the catalytic process and the determinants of its regiospecificity. Enzymes. A truncated human heme oxygenase 1 (hHO-1), consisting of amino acids 1-265 but lacking the 23 C-terminal amino acids, was used in this study (15) . The R183E mutant was generated with the Stratagene Quik-Change site directed mutagenesis kit. Oligonucleotides were synthesized by Life Technologies, Inc., through the Cell Culture Facility of the University of California, San Francisco. Plasmid purification was performed according to the protocols of Qiagen Plasmid DNA Minipreps. Transformation of DH5α competent cells was carried out by standard procedures and transformants were screened initially by ampicillin resistance and confirmed by sequence analysis. The wild-type and R183E mutant were expressed, purified and reconstituted with heme according to the published procedures, except that QA52 was used instead of the Q-Sepharose fast flow resin from Pharmacia (35) . The quality of the hHO-1 protein was determined by SDS-PAGE and the R Z (OD 404nm /OD 280nm ) value, which is 2.5 for wild-type hHO-1. Human NADPH-P450 reductase and biliverdin reductase were expressed and purified as published (19, 36, 37) .
EXPERIMENTAL METHODS

Materials
UV-visible spectra of heme-hHO-1 in the ferric, ferrous, and ferrous-CO states. The spectra for wild-type hHO-1 and its R183E mutant were recorded on a Hewlett Packard 8452A diode array spectrophotometer at room temperature in 0.1 M potassium phosphate buffer at pH 7.4. As all the subsequent experiments were performed in the same buffer, the buffer is named here the standard buffer. The ferrous and ferrous-CO hHO-1 complexes were generated by reduction of the ferric complexes with sodium dithionite and purging with CO gas. 
HPLC analysis of biliverdin isomers.
The reaction system contained heme-wild-type or heme-R183E (24 nmol), P450 reductase (~2 nmol) and NADPH (2 µmol) in standard buffer.
The total volume was 500 µL. The reaction was allowed to proceed at room temperature for 3-4 h. Three drops of hydrochloric acid (37%) plus a few drops of acetic acid were then added before the reaction mixture was extracted with 700 µL of CH 2 Cl 2 . The organic phase was washed with an equal volume of water and was then evaporated under a stream of air. The residual products were dissolved in 500 µL of methanol/5% H 2 SO 4 (v/v) and allowed to stand at 4 °C for at least 16 h. The resulting dimethyl esters were extracted with 700 µL of chloroform and washed with water twice. The organic phase was then dried under a stream of air and the residue was dissolved in 70% methanol.
Coupled oxidation with sodium ascorbate was carried out by incubating heme-wild-type or heme-R183E (10 nmol) with sodium ascorbate (3 mg) in standard buffer at room temperature for 3-4 h. The reaction volume was 500 µL. The reaction mixtures were then processed as described above for HPLC analysis. This reaction was also performed in the presence of SOD (150 units) and catalase (150 units). Crystallography. R183E hHO-1 crystals were grown under similar conditions as previously reported for wild-type human HO-1 using the sitting drop vapor diffusion method with a well solution of 2.08 M ammonium sulfate, 100 mM HEPES (pH 7.5) and 0.9% 1,6-hexanediol (38) . Drops consisted of protein stock (5 µl) at 45 mg ml -1 in 20 mM potassium phosphate (pH 7.4), mixed with well solution (5 µl) on siliconized cover slips. The only difference here is that all crystals were grown at room temperature instead of 28 °C and one round of touch seeding using crushed wild-type crystals was necessary to initiate mutant crystal growth. For cryogenic data collection D-(+)-trehalose was used as the cryoprotectant.
Cryogenic data collection involved a seven step transfer to artificial precipitant solution with increased D-(+)-trehalose concentrations up to 35% (w/v). The cell dimensions of all the crystal forms are listed in Table 1 . Data were collected using an R-AXIS IV imaging plate and an inhouse rotating anode x-ray source. Model building and refinement. R183E crystals were found to be isomorphous with hemehHO-1 crystals (21) . As a result the structure of the heme-hHO-1 complex (PDB accession number 1qq8) (21) was used as the starting model for refinement in CNS (39) . Rigid body refinement was followed by slow-cool simulated annealing to remove phase bias and the remaining cycles that followed consisted of a few cycles of conjugate gradient minimization and water picking. Finally, temperature factors were refined. No restraints for non-crystallographic symmetry were applied. The site of mutation was clearly present in the initial map and therefore was altered and included in subsequent refinement. The program O (40) was used for further adjustment and modeling of protein atoms, ligands and water molecules. Backbone geometry was checked in PROCHECK (41) , and none of the residues were in the disallowed region. 
RESULTS
UV-visible spectra of the heme:R183E hHO-1 complex
The wild-type heme-hHO-1 complex has Soret maxima at 404 and 430 nm, respectively, in the ferric and ferrous states. For the ferrous-CO-wild-type complex, the Soret band shifts to 418 nm (Fig. 2, left) . The R183E mutant exhibits the same UV-vis spectra as the wild-type in the ferric, ferrous and ferrous-CO states (Fig. 2 right) . Thus, the R183E mutation does not cause a major perturbation of the heme binding environment. (Fig. 3 right) . Reaction of heme-hHO-1 with sodium ascorbate gives Fe(III)-biliverdin, which has a spectrum with two distinct bands at 544 and 574 nm (Fig. 4, left) . In the case of the heme-R183E complex, the overall spectra upon reaction with sodium ascorbate are similar (Fig.   4, right) , but not identical, to the corresponding spectra of the wild-type enzyme (Fig. 4, left) .
Spectrophotometric monitoring of Fe(III) verdoheme, Fe(III)-biliverdin
Incubation of heme-hHO-1 with P450 reductase, biliverdin reductase, and NADPH produces bilirubin, which has a broad absorption at approximately 460 nm (Fig. 5, left) .
However, the corresponding spectra for the R183E heme complex are very different from those for wild-type hHO-1 in that three distinct absorption bands are observed at 418, 544, and 574 nm (Fig. 5, right) . These spectral changes are similar, but not identical, to those for reaction of the R183E mutant with sodium ascorbate (Fig. 4, right) .
The reaction of wild-type heme-hHO-1 with P450 reductase and NADPH gives rise to free biliverdin (λ max ~ 680 nm, Fig. 6A ). In the case of the R183E mutant, however, the resulting spectra are very different (Fig. 6B) . The presence of biliverdin reductase in the reaction does not significantly alter the spectrum that is obtained (Fig. 5. right) . This suggests that heme degradation by the R183E mutant is arrested at a step between the verdoheme intermediate and free biliverdin. Comparison of the spectra with those for the reaction of the R183E mutant with sodium ascorbate (Fig. 4, right) , which is expected to produce Fe(III)-biliverdin, shows that they both have the two distinct absorption maxima at 544 nm and 574 nm. This indicates that the iron and biliverdin products (19) .
To confirm that the species formed in the reaction of the R183E mutant with P450 reductase is Fe(III)-biliverdin, the iron chelator desferrioxamine was added to the reaction mixture to facilitate ferric iron removal. As shown in Fig. 6C , the broad absorption band around 680 nm appears, which suggests that free biliverdin is formed under these conditions. On addition of biliverdin reductase to the system, bilirubin formation is immediately observed (Fig.   6D ). The stability of the Fe(III)-biliverdin complex is such that incubation of heme-R183E with P450 reductase for prolonged periods should lead to free biliverdin formation. In accord with this inference, the absorption maxima at 544 and 574 nm slowly decreased and the biliverdin band around 680 nm became observable upon incubation of the R183E complex with P450 reductase for an extended period (~ 15-30 min) (Fig. 7, right) .
HPLC analysis of the biliverdin isomers.
All the biliverdin products isolated from the coupled oxidation of heme were converted to the dimethyl esters in order to simplify the identification by HPLC. The HPLC conditions separate the isomeric biliverdin dimethyl esters very well. As shown in Fig. 8 and Table 2 , the oxidation of heme by hHO-1 and the R183E mutant supported by P450 reductase yields only biliverdin IXα (t = 27.1 min, λ max = 375, 315, and 278 nm). Using sodium ascorbate as the electron donor, however, the R183E mutant produces 79 ± 4% of biliverdin IXα, 19 ± 3% of biliverdin IXδ (t = 29.0 min, λ max = 375 nm), and a trace of biliverdin IXβ (t = 28.5 min, λ max = 375, 310 nm). The ascorbic acid results are not unlike those reported previously for the R183E mutant of rat HO-1 (34) . In contrast, the reaction of wild-type hHO-1 with sodium ascorbate only produces biliverdin IXα. The differences in product isomers readily explain why reaction of the heme-R183E mutant complex with sodium ascorbate generates a spectrum that is similar but not identical to that obtained in the reaction supported by P450 reductase (Fig. 4, right, and Fig. 6B ).
hHO-1-dependent coupled oxidation with ascorbate was also carried out in the presence of SOD and catalase. SOD and catalase significantly inhibit the formation of biliverdin IXδ (8 ± 1% vs 19 ± 3% without) ( Table 2 ). To determine if P450 reductase helps to control the regiochemistry of oxidation even when it is not the electron donor, R183E hHO-1 was preincubated for ~35 min with P450 reductase at either a 1:1 or 1:6 ratio, respectively, before ascorbate was added. The ascorbate-dependent product profiles were not altered by the presence of P450 reductase (Table 2) .
Crystal structure of R183E hHO-1. One possible reason for multiple products in the ascorbate-driven reaction is multiple orientations of the heme in the active site. To determine if mutating R183 leads to an observable disorder, the crystal structure of the R183E mutant was determined. As in the wild-type structure, the R183E mutant has two molecules in the asymmetric unit which are referred to as "open" and "closed". In the closed conformation the distal helix is closer to the heme, thus forming a slightly tighter active site pocket that results in a 18 by guest on September 1, 2017 http://www.jbc.org/ Downloaded from more ordered active site, as judged by better electron density for the heme and active site sidechains and solvent. Fig. 9 shows the 2Fo-Fc electron density around the site of mutation in the closed molecule and shows that the mutant Glu183 side-chain is well defined.
The exact orientation of the heme is believed to be determined by interactions between the heme propionates and nearby Arg and Lys residues that fix the heme in one specific orientation (Fig. 9) . In the wild-type structure the outer heme propionate is stabilized by Lys18 and, indirectly through a water molecule, by Lys179. The inner propionate is held in place by hydrogen bonding with the hydroxyl group of Tyr134 and Arg183. The shorter Glu183 side chain is about 4.3Å away from the inner propionate. Interactions with the outer propionate also are weakened.
Lys179 occupies two orientations, one of which places the Lys equidistant (about 3.0 Å) from the inner heme propionate and the Glu183 side chain (Fig. 9) , thus helping to moderate the electrostatic repulsions between the heme propionates and Glu183. Tyr134 maintains the hydrogen bond with respect to the inner propionate.
The electron density indicates that the predominant orientation of the heme is the same as that found in wild-type hHO-1. However, in order to account for the 19 ± 3% δ-meso hydroxylation observed in the ascorbate driven reaction, the heme needs to rotate about 90 o in order to shift the δ-meso carbon into the position normally occupied by the α-meso carbon.
Based on the quality of the electron density we would be able to discern a 50:50 mix of orientations but not an 80:20 mix. Therefore, the structure is compatible with a predominantly native-like orientation but does not rule out possible alternative orientations at low occupancy. (45) . Also similar to the wild-type-NO complex, the close approach of the oxygen atom of the NO to the Gly139 peptide carbonyl oxygen (2.7 Å and 3.0 Å in the wild-type and mutant, respectively) helps to push the NO oxygen atom toward the α-meso heme carbon.
Crystal
In the wild-type NO complex NO is stabilized by a network of hydrogen bonds involving Tyr58, Asp140, Wat1, Wat2 and Thr135 (Fig. 10) . The main difference in this network in R183E-NO is the absence of Wat1 (Fig. 10) . In the wild-type-NO complex the NO oxygen (Fig. 10) . In the R183E-NO complex, however, the terminal oxygen of NO interacts with another water molecule, which we will refer to as Wat3. Wat3, which is also observed in the wild-type structure, is positioned 3.1 Å from the terminal oxygen of NO in R183E-NO and also hydrogen bonds with the side chain of Asp140 (2.6 Å) and the side chain of Leu147 (2.6 Å).
Therefore, even though the solvent structure in the mutant differs from that of the wild-type, there is still a continuous hydrogen bonded network between NO and Asp140 mediated by solvent molecules.
DISCUSSION
The heme in hHO-1 is held between two helices, one of which is quite flexible owing to the presence of three glycines in the polypeptide chain. The flexibility of this helix is evident in the relatively closed and open active site conformations observed in the two molecules in the crystallographic unit cell (21) . Furthermore, the crystal structures of the apoprotein, ferrous ligand complexes, ferric verdoheme complex, ferric biliverdin complex, and finally biliverdin complex confirm that the helices that define the heme binding site are relatively flexible (20) (21) (22) (23) (24) (25) .
In view of this active site maleability, it is important to define the features that control both the orientation of the bound heme and the regiospecificity of its oxidation.
We have demonstrated here that the heme in the R183E mutant is predominantly seated in the active site in the same orientation as the heme in wild-type hHO-1, although a low occupancy of other orientations is not inconsistent with the electron density maps. The crystal structure shows that the hydrogen bond between Arg183 and the heme propionate is disrupted in the R183E mutant. In view of this, the finding that the reaction supported by NADPH-P450 reductase still yields exclusively biliverdin IXα (Fig. 8) demonstrates that this Arg183 hydrogen bond is not essential for control of the heme oxidation regiochemistry under normal catalytic conditions. However, the diminished regiochemical control in the R183E mutant under coupled oxidation conditions unmasks the contribution of the Arg183 interaction to the specificity of heme binding.
Hydrogen bonds to the heme propionic acid residues have been found to be critical for control of the heme oxidation regiochemistry in the heme oxygenases from Pseudomonas aeruginosa and Corynebacterium diphtheriae (31) (32) (33) 46) . The pa-HO-catalyzed heme oxidation normally produces biliverdin IXδ (70%) and IXβ (30%), but disruption of the interactions between heme propionate groups and protein residues alters the regiospecificity, resulting in biliverdin IXα formation (18%) (33) . The introduction of interactions that stabilize a shifted heme orientation in pa-HO likewise result in the formation of biliverdin IXα (55%) (31) . In hHO-1, four protein residues interact with the heme propionate groups: Arg183, Lys18, Lys179, and Tyr134. Our results show that mutation of one of them, Arg183, to a glutamate is insufficient to cause heme reorientation except when the reaction is carried with ascorbate as a surrogate NADPH-P450 reductase is apparently unable to reduce ferric biliverdin to ferrous biliverdin, resulting in the accumulation of this hHO-1 complex because efficient product release requires reduction of the iron prior to sequential release of the ferrous iron and metal-free biliverdin (19) .
The inability of P450 reductase to reduce the iron presumably reflects a change in the redox potential of the metal caused by the altered electrostatic properties of the active site. This altered electrostatic environment is also likely to make reduction of the iron in the initial heme substrate more difficult.
In contrast to the situation with the reaction supported by NADPH-P450 reductase, a loss of regiochemical specificity is observed when catalytic turnover is supported by ascorbic acid ( Table 2) . Under these conditions, the R183E hHO-1 mutant yields 79 ± 4% biliverdin IXα, 19 ± 3% biliverdin IXδ, and a trace of biliverdin IXβ. This observation is consistent with the previously reported loss of stereochemical specificity observed in the ascorbate-dependent turnover of the rat R183E mutant (34) . 2 Clearly, the ascorbate-supported reaction, and coupled oxidation in general, differs from the normal reaction supported by NADPH-P450 reductase.
Studies of model reactions employing either myoglobin (47) or cytochrome b 5 mutants (48) have suggested that H 2 O 2 plays a critical role in coupled oxidation that it does not play in the normal heme oxygenase reaction. Our results with the heme oxygenase system itself concur with these model studies but also reveal the existence of two reaction processes, one inhibited by SOD and calalase, and the other relatively insensitive to these enzymes (Table 2) In sum, the α-regiospecificity of heme oxidation is preserved in the R183E hHO-1 mutant in the normal NADPH-dependent reaction, but is partially lost in the reaction supported by ascorbate. This difference suggests that (a) the ascorbate-dependent reaction differs from the normal reaction, (b) electron transfer in heme oxygenase is sensitive to relatively small changes in the active site structure and conformation, and (c) Arg183 contributes to proper binding of the heme but its contribution is not critical under normal catalytic conditions. Furthermore, the crystal structures of the R183E hHO-1 heme and heme-NO complexes show that the hydrogen bonding network required for catalysis is perturbed but in a manner that introduces a compensatory network and preserves catalytic function. The spectra were taken at 20 s intervals immediately after adding NADPH to the reaction mixture. Arrows indicate the direction of spectral change over time. 
